- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07570771
IMPACT OF DIALYSIS DURATION AND DIURESIS ON BLADDER CAPACITY AND COMPLIANCE IN END STAGE RENAL DISEASE PATIENTS AWAITING RENAL TRANSPLANT (ESRD)
Patients with end-stage renal disease (ESRD) who are on dialysis for a long time may experience bladder problems as their urine output decreases and normal bladder filling is lacking. As a result, bladder capacity may be reduced and compliance may deteriorate, which can impact the success of kidney transplantation.
Our prospective observational study is designed to investigate how dialysis duration and residual urine output (diuresis) influence bladder capacity and compliance in ESRD patients who are waiting for kidney transplantation. The adult patients undergoing regular dialysis will be assessed clinically, and they will also be subjected to laboratory tests, imaging, and urodynamic studies.
Through this study, we aim to determine the frequency of bladder malfunction and its correlation with the length of dialysis and the amount of urine excretion. The results might enhance the pre-transplant workup and offer a basis for urological post-transplantation management that could minimize complications.
Study Overview
Status
Intervention / Treatment
Detailed Description
End-stage renal disease (ESRD) is related to major changes in lower urinary tract functions, mainly due to decreased urine production and prolonged bladder inactivity during dialysis. Therefore, the bladder might shrink and get stiff, the muscle of the bladder can contract involuntarily, and other abnormalities of urine storage and voiding can be detected.
Such urodynamic changes have fairly good clinical relevance since impaired bladder function not only increases the susceptibility to urinary tract infections, but also to vesicoureteral reflux, and it can have negative effects on renal transplant outcomes.
Dialysis duration and loss of residual urine production capacity are recognized as the main factors affecting bladder function. Dialysis patients who have been on the treatment for a long time and are anuric will develop more bladder dysfunction and damage than those with preserved urine output.
This prospective observational study is planned to take place at Sindh Institute of Urology and Transplantation (SIUT), Karachi, Pakistan. Adult patients aged 18-65 years with end-stage renal disease on maintenance dialysis for 6 to 24 months and awaiting renal transplantation will be enrolled through consecutive sampling.
After getting the informed consents, demographic and clinical data will be recorded, such as age, gender, body mass index, cause of ESRD, duration of dialysis, and urine output, which will be measured by a frequency-volume chart. The initial work-up will include examination of the urine, urine culture, and ultrasound examination of the kidneys, ureters, and bladder with measurement of post-void residual volume.
All eligible patients will be further evaluated with cystoscopy, uroflowmetry, and video-urodynamic studies to assess bladder morphology and function. The main outcome variables are bladder capacity and bladder compliance, whereas secondary variables include maximum urinary flow rate (Qmax), post-void residual volume, and the presence of lower urinary tract symptoms.
The acquired data will be statistically analyzed using appropriate methods to identify possible relationships between dialysis duration, diuresis status, and bladder function parameters. This study is conducted with the aim to estimate the prevalence of clinically significant bladder dysfunction and to identify high-risk patients who may benefit from early urological intervention prior to renal transplantation.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Dr. Anum Fatima Parekh, FCPS
- Phone Number: +92-333-3305227
- Email: anum.parekh@yahoo.com
Study Contact Backup
- Name: Dr.Mohsin Memon, FCPS
Study Locations
-
-
Sindh
-
Karachi, Sindh, Pakistan, 74200
- Recruiting
- Sindh Institute of Urology and Transplantation (SIUT)
-
Contact:
- Anum Fatima Parekh, FCPS
- Phone Number: +92-333-3305227
- Email: anum.parekh@yahoo.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients aged 18-65 years diagnosed with end-stage renal disease (ESRD)
- Patients on maintenance dialysis for a duration of 6 to 24 months
- ESRD secondary to non-urological causes
- Patients awaiting renal transplantation
Exclusion Criteria:
- Patients with diabetes mellitus
- Patients with neurogenic bladder
- Patients with prior urological surgeries
- Patients with active urinary tract infection
- Patients with pre-existing lower urinary tract symptoms before dialysis
- Patients on medications affecting lower urinary tract function
- Patients with neurological or systemic diseases affecting bladder function
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Oliguric Patients
Patients with end-stage renal disease (ESRD) on maintenance dialysis with residual urine output between 100-400 mL/day undergoing observational assessment of bladder capacity and compliance using urodynamic studies.
|
This is a prospective observational study with no therapeutic or preventive intervention.
Participants undergo clinical assessment, including evaluation of dialysis duration and residual urine output, along with laboratory investigations, imaging, and urodynamic studies to assess bladder capacity and compliance.
|
|
Anuric Patients
Patients with end-stage renal disease (ESRD) on maintenance dialysis with urine output less than 100 mL/day undergoing observational assessment of bladder capacity and compliance using urodynamic studies.
|
This is a prospective observational study with no therapeutic or preventive intervention.
Participants undergo clinical assessment, including evaluation of dialysis duration and residual urine output, along with laboratory investigations, imaging, and urodynamic studies to assess bladder capacity and compliance.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Bladder Capacity
Time Frame: At time of urodynamic evaluation (baseline)
|
Bladder capacity is measured in milliliters (mL) using video urodynamic study (VUDS) at the time of evaluation, defined as the maximum cystometric capacity at which the patient is given permission to void.
|
At time of urodynamic evaluation (baseline)
|
|
Bladder Compliance
Time Frame: At time of urodynamic evaluation (baseline)
|
Bladder compliance measured in mL/cm H₂O using a video-urodynamic study is calculated as the change in bladder volume divided by the change in detrusor pressure during the filling phase.
|
At time of urodynamic evaluation (baseline)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Post-Void Residual Volume
Time Frame: At baseline evaluation
|
Measured in milliliters (mL) using ultrasound after voiding.
|
At baseline evaluation
|
|
Maximum Urinary Flow Rate (Qmax)
Time Frame: At baseline evaluation
|
Measured in mL/sec using uroflowmetry.
|
At baseline evaluation
|
|
At baseline evaluation
Time Frame: At baseline evaluation
|
Presence of lower urinary tract symptoms assessed clinically and recorded as a categorical variable (present or absent).
|
At baseline evaluation
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- SIUT-ERC-2025/A-611
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bladder Dysfunction
-
University of California, San FranciscoRecruitingBladder Dysfunction | Postpartum Bladder Dysfunction | Post-prostatectomy Bladder DysfunctionUnited States
-
Gérard AmarencoCompleted
-
Halil TugtepeBahçeşehir UniversityCompletedBladder and Bowel Dysfunction, Femoral Anteversion | Bladder and Bowel Dysfunction, Hip Strength Ratios | Bladder and Bowel Dysfunction, Pelvic AngleTurkey
-
Sohag UniversityRecruiting
-
Wellspect HealthCareWellspect HealthCareTerminatedBladder Voiding DysfunctionGermany
-
University of AarhusUnknownDysfunction of the Urinary BladderDenmark
-
Ulrich MehnertNCCR (National Center of Competence in Resaerch, Switzerland)CompletedHealthy | Neurogenic Bladder Dysfunction Nos | Nonneurogenic Neurogenic Bladder DysfunctionSwitzerland
-
University of Colorado, DenverNational Cancer Institute (NCI); National Institute of Diabetes and Digestive... and other collaboratorsRecruitingBladder Dysfunction | Survivors of Childhood CancerUnited States
-
National Academy of Medical Sciences, NepalCompletedSexual Dysfunction | Colorectal Surgery | Bowel Dysfunction | Bladder Dysfunction
-
Children's Hospital of Orange CountyEnrolling by invitationBladder and Bowel DysfunctionUnited States
Clinical Trials on Observational Assessment
-
Istanbul Medeniyet UniversityRecruitingDysfunctional Breathing | Smartphone Addiction | Postural DisordersTurkey (Türkiye)
-
Stefan LujinschiInstitutul Clinic FundeniNot yet recruitingPeriodontitis | Chronic Kidney Disease | CKD | Fabry Disease | Periodontal Disease | Systemic Lupus Erythematosus (SLE) | Alport Syndrome | Lupus or SLE | Tuberous Sclerosis Complex (TSC)Romania
-
Dr Abdurrahman Yurtaslan Ankara Oncology Training...RecruitingPostoperative Pain | Pain Management | Analgesic ConsumptionTurkey (Türkiye)
-
Marmara UniversityRecruitingMultiple Sclerosis | Spasticity | Spasticity With Multiple SclerosisTurkey (Türkiye)
-
Ondokuz Mayıs UniversityCompleted
-
Medipol UniversityMudanya UniversityActive, not recruitingEating Disorders | Bariatric Surgery | Emotional Eating | Obesity & Overweight | Weight Regain Post Bariatric SurgeryTurkey (Türkiye)
-
Biruni UniversityCompletedPeriodontitis | Periodontal Diseases | Health Education | Health Behaviour | Oral Health LiteracyTurkey (Türkiye)
-
Ezgi TurkyilmazCompletedDental CariesTurkey (Türkiye)
-
Balikesir UniversityRecruitingCognitive Function | Gait | Foot BiomechanicsTurkey (Türkiye)
-
Ondokuz Mayıs UniversityRecruitingSarcopenia | Malnutrition Severe | Lung Cancer (Non-Small Cell)Turkey (Türkiye)